Looking for the bestsellers? Here’s a link to the official New York Times Bestsellers!
Want to read a bestseller that’s a little more obscure? Try the Indie Bestsellers!
Want our personal recommendations? Here are our Staff Picks! All staff picks are 15% off, but these are our favorites this month.
Dylan’s pick for March is Killing Season by Faye Kellerman.
This thriller had just enough twist and turns to keep me guessing every step of the way. 16 year old Ben becomes obsessed with his older sister Ellen’s unsolved murder. He gathers evidence, finds patterns, takes it upon himself to visit crime scenes, and gets the new girl at school involved in his secrets. Only involving the detective when he needs to, Ben suddenly finds he has no only stumbled across key information, but maybe the killer knows he is close to figuring it out. This book was intense.
Gabriella’s pick for March is Mañanaland by Pam Muñoz Ryan.
In this lightly enchanting middle grade novel, Ryan weaves a tale of courage and quiet justic sorely needed at this moment.
Max has listened to his Buelo’s stories about a guide who leads travelers to tomorrow, but that’s all they are, his father insists–stories. But rumors to the contrary fly around Santa Maria, and Max is determined to find out the truth for himself. What he discovers firsthand goes far deeper than he expects, and will completely alter his ideas about family, hope, and tomorrow.
Ready for more? Come to the store and check out our Staff Picks shelf!
If you’re reading along with WCMY, here’s our book for discussion in March!
The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: The technology didn’t work.
For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company’s value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.